novo glp-1 Nordisk: A New Boost for Sales on the Horizon Novo Nordisk testing its blockbuster

The Food and Drug Administration (FDA) recommends people who have a personal or family history of medullary thyroid cancer (MTC) should not use Zepbound along with people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Meanwhile, the antioxidant-rich Green Tea Extract further amplifies fat oxidation, boosts metabolic rate, and supports cardiovascular and immune health

[Abstract] Hepatology

Emerging research is exploring the connection between GLP-1 receptor agonists and mood, raising questions about their broader implications for mental well-being

Tirzepatide has been approved for T2D management - the mean HbA1c reduction in SURPASS programme ranged between 1.9 and 2.6% across the trials and 4069% of participants achieved 10% WL with the higher doses (10 and 15 mg), despite that there was no additional support for lifestyle intervention [16, 43]